advertisement
Abstract #3623 Published in IGR 4-2
Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test
Stewart WC; Stewart JA; Crockett S; Kubilus C; Brown A; Shams NActa Ophthalmologica Scandinavica 2002; 80: 272-276
PURPOSE: To compare the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test. METHODS: Thirty subjects aged 18-37 years (mean age, 24.1 years) were randomized to one of six treatment sequences in a three-treatment, three-period crossover study (William's design). Study medication was instilled b.i.d. for five days before visits 2, 3, and 4. Between treatments, study medication was washed out for nine to ten days. Each subject underwent a submaximal treadmill test at visits 2 through 4, 15 minutes after dosing. RESULTS: After 15 minutes of exercise, average heart rates were 143.1 ± 21.2, 134.5 ± 20.0 and 145.4 ± 20.8 bpm for the unoprostone, timolol and placebo treatments, respectively. At no timepoint was there a statistically significant difference between the unoprostone and placebo treatments (p > 0.05). Beginning with the second minute of exercise, timolol produced a greater decrease in heart rate at all timepoints from placebo than unoprostone (p < 0.05). No consistent differences in systolic or diastolic blood pressure were observed between drug treatments (p > 0.05). CONCLUSIONS: Unlike timolol, unoprostone 0.15% does not reduce exercise-induced heart rate, indicating a lack of clinical effect on systemic beta-adrenergic receptors in young and healthy subjects.
Dr. W.C. Stewart, Pharmaceutical Research Corporation, 1639 Tatum Street, Charleston, SC 29412-2464, USA
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
